The EULAR revised recommendations for the management of fibromyalgia emphasize evidence-based approaches, incorporating recent research and systematic reviews. The guidelines recommend a graduated approach, starting with non-pharmacological therapies such as exercise, which is strongly recommended due to its effectiveness in reducing pain and improving physical function. If non-response occurs, other therapies including psychological interventions, pharmacotherapy, and multimodal rehabilitation may be considered. Pharmacological treatments like amitriptyline, pregabalin, and duloxetine are classified as 'weak for' based on available evidence, while others such as growth hormone and sodium oxybate are strongly against due to safety concerns. Non-pharmacological therapies like acupuncture, biofeedback, and cognitive behavioural therapy are also evaluated, with some receiving 'weak for' recommendations. The guidelines highlight the importance of individualized treatment based on patient needs and emphasize the need for further research to clarify the effectiveness of various interventions and optimize healthcare systems. The recommendations are supported by high-quality reviews and meta-analyses, but the overall effect sizes of most treatments are modest. The guidelines aim to improve the management of fibromyalgia by providing clear, evidence-based recommendations for both pharmacological and non-pharmacological approaches.The EULAR revised recommendations for the management of fibromyalgia emphasize evidence-based approaches, incorporating recent research and systematic reviews. The guidelines recommend a graduated approach, starting with non-pharmacological therapies such as exercise, which is strongly recommended due to its effectiveness in reducing pain and improving physical function. If non-response occurs, other therapies including psychological interventions, pharmacotherapy, and multimodal rehabilitation may be considered. Pharmacological treatments like amitriptyline, pregabalin, and duloxetine are classified as 'weak for' based on available evidence, while others such as growth hormone and sodium oxybate are strongly against due to safety concerns. Non-pharmacological therapies like acupuncture, biofeedback, and cognitive behavioural therapy are also evaluated, with some receiving 'weak for' recommendations. The guidelines highlight the importance of individualized treatment based on patient needs and emphasize the need for further research to clarify the effectiveness of various interventions and optimize healthcare systems. The recommendations are supported by high-quality reviews and meta-analyses, but the overall effect sizes of most treatments are modest. The guidelines aim to improve the management of fibromyalgia by providing clear, evidence-based recommendations for both pharmacological and non-pharmacological approaches.